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Abstract
Hepatic venous outﬂow obstruction (HVOO) is common in developing countries. It is a serious condition that clinically manifests
with ascites from sinusoidal hypertension, and carries the risk of high mortality or development of liver cirrhosis. In the past,
the eponym Budd–Chiari Syndrome (BCS) was used synonymously for HVOO. In theWest, hepatic vein (HV) thrombosis caused
by prothrombotic disorders is the main cause of HVOO. In the East, obliterative disease of hepatic portion of inferior vena cava
induced by bacterial infection, now renamed hepatic vena cava syndrome, is the common cause of HVOO. These two diseases
with different etiology, epidemiology, and natural history are at present grouped together under BCS causing much confusion.
Sinusoidal obstruction syndrome, another important cause of HVOO at the level of the sinusoid and terminal HV, was left
out in the classiﬁcation of HVOO. In this article, the pathophysiology of sinusoidal hypertension is described, the term BCS is
redeﬁned, and a new classiﬁcation of HVOO is suggested.
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Introduction
Liver is a highly vascular organ with dual blood supply from
hepatic artery and portal vein (PV). Normal hepatic blood
ﬂow is about 1500 mL/min. PV blood contributes approxi-
mately 70% of the ﬂow and 50% of the oxygen consumed
by liver. Blood from hepatic artery at about 100 mmHg pres-
sure and PV at about 10 mmHg pressure mixes in the hepatic
sinusoid. In contrast to other capillaries whose endothelial
linings are continuous, the sinusoidal capillaries are lined by
discontinuous layer of endothelium that has pores of about
30–50 nm in size called fenestrae grouped into sieve plates (1).
The liver sinusoids are also noted by the absence of a demon-
strable basement lamina. Thus, the endothelium is highly
permeable and largely supported by a carpet-like pile
formed by liver cell microvilli separated by the space of
Disse. Hepatic microcirculation is characterized by low out-
ﬂow resistance. The ratio of pre- to post-capillary resistance
in skeletal muscle is 4:1 compared to 49:1 in the liver, which
results in a very low outﬂow resistance (2). Maintenance
of low sinusoidal pressure is important for normal hepatic
function. This is helped by another unique interrelationship
between the sinusoidal pressure and the hepatic arterial
ﬂow. Increase in sinusoidal pressure results in reﬂex decrease
in hepatic arterial ﬂow (3). Thus, despite increase in portal
venous ﬂow during digestion, the sinusoidal pressure is main-
tained low. The size of the pore in hepatic sieve plate is just
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right at normal sinusoidal pressure to maintain an oncotic
gradient that prevents loss of protein into interstitial space.
The anatomy of hepatic microcirculation is adjusted to
allow the hepatocytes a close contact with the incoming PV
blood rich in nutrients and hormones, a process that facili-
tates liver to play its role in body metabolism.
Clinical manifestation of HVOO
Sinusoidal blood that drains into terminal hepatic vein (HV)
is collected in lobular and sublobular veins that join to form
medium-sized veins. Medium-sized veins join to form large
HVs. Three large and nearly 20 small HVs drain the liver
blood into inferior vena cava (IVC), which carries it to the
right atrium of the heart. Hepatic venous outﬂow obstruction
(HVOO) may occur at the level of the sinusoids, at HVs, or
IVC at the HV outlets. Oriﬁces of large HVs are considered
by some as part of the IVC system (4). HVs have no valve
and any increase in IVC pressure is directly transmitted to
the liver. Thus, cardiac condition such as constrictive pericar-
ditis mimics HVOO (5).
The clinical manifestation of HVOO largely depends on the
extent and speed of obstruction, its cause, and the develop-
ment of compensatory mechanisms. Obstruction of a few
medium-sized HVs or a large HV may not cause any symp-
tom. Insidiously developing multiple HV obstruction that
allows development of collaterals also remains asymptomatic.
HV obstructions thus may largely remain asymptomatic
for variable period, till a large part of hepatic outﬂow tract
is obstructed, resulting in sudden increase in sinusoidal pres-
sure. Sinusoidal hypertension manifests clinically as ascites.
Sinusoidal hypertension and ascites occur and reoccur at
any time in the course of the diseases of HV and IVC.
Pathophysiology of sinusoidal hypertension
Development of ascites
HVOO that results in sinusoidal hypertension (Figure 1)
causes sinusoidal dilatation and drop in the intra-hepatic
blood ﬂow. Because of the unique anatomic feature of the
hepatic sinusoid, sinusoidal hypertension is followed by
rapid ﬂow of protein-rich ﬂuid into the space of Disse. The
protein concentration in the interstitium approaches that of
plasma with loss of oncotic gradient between the blood and
space of Disse. The ﬂuid that enters the space of Disse is
removed by the lymphatics. Increased formation of lymph
occurs. When it exceeds the draining capacity of the lympha-
tics, it oozes out into the peritoneal cavity. Droplets of lymph
oozing from the dilated lymphatics on the surface of the liver,
labeled as “weeping liver,” had been observed during laparo-
scopy and surgery. Fluid that enters the abdomen is absorbed
by the lymphatics of the peritoneal cavity, principally by
diaphragmatic lymphatics. The amount of ascites that accu-
mulates reﬂects a balance between rates of formation and
absorption. The rate at which ascites is formed is determined
by the sinusoidal pressure, the permeability characteristic of
hepatic sinusoids, and the capacity of lymphatics to drain.
The rate at which ascitic ﬂuid is removed is determined by
the nature of the peritoneal membrane and intraperitoneal
pressure. The thickening of the peritoneal membrane slows
the rate of absorption of ascitic ﬂuid. Ascites in hepatic
vena cava syndrome (HVCS) is associated with bacterial peri-
tonitis resulting in thickened peritoneum (6). Slow rate of
removal of ascitic ﬂuid from peritoneal cavity, combined
with persistence of bacterial infection, leads to development
of chronic peritonitis in HVC (7).
Sodium retention by kidneys
Ligation of IVC immediately above HV opening is followed
by increase in sinusoidal pressure and development of
ascites. Levy and Wexler (8) observed that dogs with low-
grade caval obstruction developed sodium retention which
could be prevented by subjecting the animal to complete
hepatic denervation before caval ligation. In dogs with high
caval obstruction and ascites mobilized by peritoneovenous
shunt, hepatic denervation resulted in normal sodium balance
despite high sodium intake. In contrast, non-denervated
animals with high-grade caval obstruction and a peritoneove-
nous shunt developed positive sodium balance irrespective
of their sodium intake and developed anasarca with high-
sodium diet. The stimulus to sodium retention by kidneys
arises in sinusoidal wall and is mediated by hepatic barore-
ceptors. Sodium retention further aggravates the ascites,
and is responsible for symptoms like puffy face and swelling
of hands and legs in these patients.
Liver damage in sinusoidal hypertension
Sinusoidal hypertension with associated reﬂex reduction of
hepatic arterial inﬂow results in centrilobular ischemic liver
damage. Liver biopsy in patients with acute HVOO shows
thickened or obstructed centrilobular vein wall, sinusoidal
dilatation, centrilobular hemorrhagic inﬁltration, and atro-
phy of hepatic cord. The extinct liver parenchyma is replaced
by ﬁbrosis within a few weeks. Regenerative activity of the
unaffected liver cells around portal tract, as indicated by
liver cells that are bigger and often arranged in double
layer, attempts to maintain normal parenchymal function.
The process ultimately leads to the development of veno-centric
liver cirrhosis (LC) with dense ﬁbrosis largely conﬁned to
peri-venular area. Patients with HVCS often have associated
endophlebitis of medium-sized HVs and PVs. The associated
ischemic liver damage eventually results in development of
veno-portal type of cirrhosis (9–11). Development of LC
within 3–9 months of liver biopsy for acute diseases has
been documented in patients with sinusoidal obstruction syn-
drome (SOS) (12, 13), Budd–Chiari syndrome (BCS) (14),
and HVCS (11). Thus, unlike in liver disease due to alcohol
or chronic hepatitis B or hepatitis C where it takes 20–25
years of exposure for the agent for LC to develop, in
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sinusoidal hypertension, cirrhosis develops rapidly. HVCS-
induced LC is characterized by many distinct clinical, ultraso-
nography, and color Doppler (US/CD) features (15).
Leopold et al. (16), based on histological study of biopsies
and postmortem tissue from cases with HVOO, have put
forth evidence that an early event in sinusoidal hypertension
is the exit of blood cells from sinusoid into space of Disse
where they become intermingled with the cells of liver plates.
Blood cells dissecting and compressing the columns of liver
cell plates result in atrophy and necrosis of hepatocytes
(16). Similar changes were also reported in the experimental
HV ligation (17) and in patients with heart failure (18).
Sinusoids are frequently dilated and empty in the biopsies
but are seen engorged with blood cells in the postmortem
livers. Sinusoidal congestion seen in postmortem histology
is interpreted as agonal change or postmortem reﬂux from
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Figure 1. Pathophysiology of sinusoidal hypertension.
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the great veins. Effects in liver due to HV occlusion and heart
failure are similar. Sherlock who studied 41 liver biopsies
from cases of clinical heart failure had mentioned of the
agonal and postmortem changes that may aggravate the
degree of parenchymal damage present during lifetime (19).
Sinusoidal hypertension is associated with decreased PV
inﬂow. Slow PV ﬂow combined with presence of infection
in HVCS and hypercoagulable state in BCS results in throm-
bophlebitis or thrombosis of PV and its branches. Secondary
thrombosis of PV in HVCS was described by Chiari (20).
Parker observed this complication in 20% of the cases (21).
Tanaka and Wanless, in their study of 15 resected livers
from patients with BCS, detected severe PV obstruction by
thrombosis and presence of veno-portal cirrhosis in six livers,
and moderate PV obstruction in another six livers, that
showed mixed veno-centric and veno-portal cirrhosis (22).
Similarly, Kage et al. reported ﬁbrosis of portal tract in
livers with congestive ﬁbrosis and congestive cirrhosis
due to HVCS (23). Diffuse, thickened echoic wall of PV
and its branches with occasional thrombosed branches are
frequently observed in US/CD examination of patients with
HVCS. Whereas HVCS is a common cause of PV thrombosis
in Nepal, in India, it was reported only in patients with LC
and HCC related to prothrombotic conditions (24).
The liver damage in sinusoidal hypertension due to HVOO
is thus not limited to acute congestive changes around
terminal HVs as was previously considered, but different
mechanisms of liver parenchymal damage operate in patients.
These include dissection of blood into liver trabeculae,
ischemic injury due to occlusion of HV and PV, and ischemic
injury of sinusoidal linings by release of free radicals (25). The
outcome of liver damage, however, is inﬂuenced by compen-
satory mechanisms that come into play: the regenerative
activity of the unaffected hepatocytes especially around
portal tract, and the development of collaterals between
obstructed and patent veins in and around the liver.
Present classiﬁcation of HVOO
At present, the eponym BCS is used synonymously for
HVOO (26–29). In the past, it had been used for various
entities, as some used it for thrombosis of large HVs, others
for both thrombotic and non-thrombotic lesions of large
HVs and IVC between the liver and right atrium, and a few
used it even when the obstruction was in the right atrium.
As the term “BCS” became ambiguous that neither identiﬁes
the morphology nor the site of obstruction nor the etiology of
the disease, Ludwig et al in 1990 suggested dropping the use
of the term (4) which was supported by Okuda (30). In their
original papers, Budd described three cases of hepatic vein
thrombosis (HVT) subsequent to abscess-induced phlebitis
which he ascribed to sepsis and alcoholism or syphilis (31),
and Chiari (1898) described another three cases of “phlebitis
obliterans” where microscopic lesion had extended to adja-
cent segment of IVC (20). Similar cases were described by
Raynaud in 1827 (32) before Budd, and by many including
Wilks (33) and Osler (34) before Chiari. Justiﬁcation for
the continued use of the eponym thus appears tenacious.
However, an international panel from Europe in 2003 advo-
cated retaining BCS because of its long usage and deﬁned it as
HVOO wherever the level or mechanism of obstruction, with
exclusion of SOS and cardiac and pericardial diseases (26).
BCS was divided into primary BCS when related to a primar-
ily venous disease (thrombosis or phlebitis), and secondary
BCS when related to compression or invasion by a lesion
originating outside the vein (benign or malignant tumor,
abscess or cyst). Further classiﬁcations according to its loca-
tion (small HVs, large HVs, IVC, and combination obstruc-
tion of large HVs and IVC) have been suggested. And it
has become a common practice to classify HVOO based on
the level of obstruction into HV block, IVC block, and com-
bined HV and IVC block (35–38). Classifying HVOO on the
basis of the site of obstruction is not helpful as the site of
obstruction in the HVOO tract does not differentiate primary
diseases of HVOO and it does not inﬂuence the management.
In BCS, lesions develop not only in large HVs but also in
medium, small, and terminal HVs (21, 22) and now it appears
even at the level of sinusoid. Similarly, in HVCS, besides
primary lesion in IVC, lesions develop at different levels in
HVs as in BCS (23). Patients or livers, both in BCS and
HVCS have multiple lesions not only at different levels
in HVs but also in PV and its branches (21–23). There was
also a suggestion to classify HVOO as due to thrombotic
and non-thrombotic lesions; in non-thrombotic group, webs
and membrane were included with tumor or other obstructive
anomalies (4). It is now well recognized that not only webs,
membrane, and stenosis but even calciﬁcation of the lesions
in HV and IVC is the sequel of initial thrombosis or throm-
bophlebitis (21–23), and their presence indicates the duration
of the disease process.
HVOO is rare in the West where it is predominantly due to
HVT caused by a combination of inherited and acquired
thrombogenic conditions of which myeloproliferative disor-
der is the common (26, 39, 40). HVOO is common in the
East where it is an important cause of portal hypertension
(41, 42), ascites (6), and LC (11, 15, 43), and is predominantly
due to the disease of the hepatic portion of IVC (43–59).
Okuda and colleagues in 1998 established this disease as a
distinct clinical entity (60). The epidemiology, etiology, and
clinical course of the disease of IVC are different from
HVT (61) and it is now renamed HVCS and a new concept
of pathogenesis of the disease based on bacterial infection
etiology has recently been put forth (7). In India, both
HVCS and HVT occur. In practice, Western investigators
had been using the term “BCS” to mean HVT due to throm-
bogenic conditions, whereas investigators in the East used it
for HVCS and HVT. Vascular surgeons in the East used it
for HVCS (38, 59). The term “BCS” thus continued to be
used by different people to mean different things. Interpreta-
tion of the results of the studies and assessment of prognosis
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and treatment of BCS from different centers are thus not
comparable. Inclusion of HVT and HVCS together under
BCS has been a source of confusion that resulted in patients
from developing countries with HVCS subjected to costly
investigations for thrombotic disorders. To avoid these con-
fusions, need is felt to redeﬁne the term “BCS” and suggest
a meaningful classiﬁcation of HVOO.
Proposed new classiﬁcation of HVOO
• The term “BCS”, instead of using it synonymously
with HVOO, is used to indicate only the prothrombotic
disorders–induced thrombosis of HVs or IVC as was
used by Valla (14).
• HVCS, bacterial infection–induced thrombotic or non-
thrombotic obstruction of IVC at or near the HV outlet,
is recognized as a separate disease entity and not clubbed
together with prothrombotic conditions–induced HVT.
• SOS, non-thrombotic obstruction at the level of sinusoid
caused by pyrrolizidine alkaloid or myeloablative therapy
which was left out of classiﬁcation of HVOO, is included
in it.
• SOS, BCS, and HVCS that originates from the venous
wall or the venous lumen of HV and IVC near HV outlet
are considered primary diseases of HVOO (Figure 2).
• HVOO is considered secondary when it is caused by com-
pression or invasion of HV or hepatic portion of the IVC
by lesion arising outside the vein, such as tumor, abscess,
or cyst. A brief account of the three primary diseases of
HVOO is given in Table 1.
Primary diseases of HVOO
Sinusoidal obstruction syndrome
This disease was ﬁrst described in South Africa in 1920 in a
family who developed cirrhosis with ascites after eating bread
made from wheat contaminated with seeds of Senecio. Brass
and colleagues later reported similar non-portal–type cirrhosis
among inhabitants of Jamaica who drank herbal tea containing
pyrrolizidine alkaloid (62) and named it veno-occlusive disease
(VOD). The disease had occurred in the former Soviet Union
(63). From 1975 to 1977, three outbreaks of the disease were
reported from South Asia, two from India, and one from
Afghanistan (64–66). Until the advent of chemotherapy in
1950, ingestion of herbal teas or food sources contaminated
with pyrrolizidine alkaloids was the only cause of VOD.
Later, the disease was reported among patients receiving
long-term immunosuppressant after renal or liver transplanta-
tions (67) and in patients with bone marrow transplantation
(68). As the injury to the liver in the disease is initiated by
changes in the sinusoid, it was renamed SOS (69).
SOS is caused by toxic injury to hepatic sinusoids by pyrro-
lizidine alkaloid or myeloablative therapy. Major event in the
disease is the rounding up or swelling of sinusoidal endothe-
lial cells that results in dissection of the sinusoidal lining,
which embolizes and blocks the microcirculation causing
sinusoidal hypertension. The disease is characterized clini-
cally by weight gain from sodium retention, hepatomegaly,
ascites, and jaundice, and histologically by diffuse damage
to centrilobular zone of the liver. Majority of the patients
respond to management of sodium and water balance with
diuretics and repeated paracentesis (69).
Hepatic Venous Outflow Obstruction
(Obstruction to blood flow from sinusoids to Hepatic Vein Outlets
In Inferior Vena Cava)
Primary HVOO   
(Endoluminal venous lesion
Thrombosis/thrombophlebitis/stenosis/
Membrane)
Secondary HVOO
(Compression by lesion 
outside the venous system
-tumor, abscess, cyst)
Sinusoidal Obstruction 
Syndrome
Budd Chiari
Syndrome
Hepatic Vena Cava 
Syndrome
Figure 2. Suggested classiﬁcation of hepatic venous outﬂow obstruction.
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Budd–Chiari syndrome
BCS is a rare disease reported mainly fromWestern countries.
Its prevalence is about 1:100,000 populations, with 80% of
the cases occurring in women around 30 years of age. BCS
was also reported in India. Myeloproliferative disorders
are the most common cause of BCS (14, 29). Symptomatic
HVT has been observed in 1% of the patients with primary
myeloproliferative disease. Other conditions associated
with BCS include antiphospholipid syndrome, paroxysmal
nocturnal hemoglobinuria, antithrombin deﬁciency, protein
S deﬁciency, protein C deﬁciency, and factor V Leiden.
Recently, it has been increasingly recognized that a combina-
tion of several thrombogenic conditions and a triggering
factor are necessary for the occurrence of HVT (14).
BCS patients with myeloproliferative disorders have, on
average, higher platelet counts and a larger spleen. Clinical
manifestation depends on the extent and speed of the obstruc-
tive process that vary from acute hepatic failure to asympto-
matic condition detected fortuitously. BCS with HVOO
presents with upper abdominal pain, hepatomegaly, and
ascites with moderate alteration of liver tests in persons
with known risk factors for thrombosis. US/CD examination
is the ﬁrst choice of investigation. Treatment is aimed at pre-
venting further extension of the thrombosis into other HVs
with the use of anticoagulants, and managing complications.
For initiating anticoagulation, low-molecular-weight hepar-
ins are generally preferred. Depending on the seriousness
of the case, the treatment options for BCS include life-
long anticoagulation, angioplasty and stenting, transjugular
intrahepatic portosystemic shunt, surgical shunt, or liver
transplantation (40). BCS is a disease with well-deﬁned
etiology, natural history, and managements.
Hepatic vena cava syndrome
HVCS is a bacterial infection–induced disease of the hepatic
portion of the IVC (7, 70). The initial lesion in IVC is a loca-
lized thrombophlebitis at the site where HV opens, which
on resolution converts the segment into a localized stenosis
or complete obstruction. Circulatory balance is maintained
by development of many pathways of cava-caval collateral
anastomosis (71). The disease is characterized by long asymp-
tomatic period and recurrent acute exacerbations (AEs) pre-
cipitated by clinical or subclinical bacterial infection with
deposition of fresh thrombus at the site. It is complicated
by high incidence of LC and moderate incidence of hepatocel-
lular carcinoma (11). HVCS is a disease of people living in
poor hygienic living conditions. It is common in developing
countries. It affects people of all ages with high incidence in
the second and third decades of life, with a slight increased
incidence in males.
The initial lesion or the thrombus formed during severe
AE may extend into HV outlets, resulting in HVOO with
sudden development of ascites (Figure 3). Severe AE is likely
to develop in persons with poor nutrition or history of alcohol
abuse precipitated by puerperal sepsis, chronic bacterial
diarrhea, or surgical operation (72, 73). Fever and jaundice
usually preceded ascites which is associated with neutrophil
Table 1. Three primary diseases of hepatic venous outﬂow obstruction.
Types
Sinusoidal obstruction
syndrome
Budd-Chiari syndrome Hepatic vena cava syndrome
Primary site of lesion
Secondary site/s
Sinusoidal endothelium
Terminal hepatic vein
Hepatic veins
PV/IVC
Hepatic portion of IVC
HV ostia/HV/PV
Etiology
Toxic injury
-Pyrrolizidine alkaloids
-Immunosuppressive drugs
Prothrombotic disorders
Bacterial infection
-Thrombophlebitis
Epidemiology
In person with
-organ transplantation/
-use of PA containing herbs
Outbreak due to contamina-
tion of wheat with PA
containing seeds
Rare
Endemic in developing
countries
Clinical
Acute: hepatomegaly,
ascites, jaundice mild/
moderate/severe
Acute/subacute/chronic/
rarely fulminant
Chronic with recurrent acute
exacerbations and cava-caval
collaterals
Outcome Spontaneous recovery/LC
Acute liver failure
Treated with anticoagulant
Respond to treatment with
antibiotic
LC and HCC common
IVC, inferior vena cava; HV, hepatic vein; PV, portal vein; LC, liver cirrhosis; HCC, hepatocellular carcinoma; PA, pyrrolizidine alkaloid.
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leukocytosis, elevated level of C-reactive protein (CRP),
and or bacteremia. Ascites in HVCS is invariably associated
with bacterial peritonitis (6). About 15% of patients develop
pleural effusion (74). US/CD examination (75) and labora-
tory tests that include total and differential white blood cells
(WBC), culture of blood and ascitic ﬂuid, and estimation
of CRP are diagnostic of ascites from severe acute/AE of
HVCS. This condition responds to treatment with high-dose
oral antibiotic for 6–8 weeks, salt restriction, and diuretics.
Diﬀerential diagnosis of primary diseases
of HVOO
Ascites is an important clinical manifestation of the primary
diseases of HVOO. Sudden development of hepatomegaly
and ascites with high protein content (usually >2.5 g/dL),
and high serum-ascitic albumin gradient is due to HVOO.
SOS is the likely cause when this type of ascites develops in
a patient on myeloablative therapy or persons using herbal
tea. US/CD shows enlarged liver with no abnormality in
HV and IVC. SOS had occurred as epidemic outbreaks
in underdeveloped areas of developing countries, especially
during periods of draught. Outbreak of jaundice with
ascites in such circumstances indicates to SOS caused by
pyrrolizidine alkaloids. Even dogs in the affected area are
known to develop ascites during the outbreak.
HVCS develops in any age group of either sex. Ascites in
HVCS is common in persons with poor nutrition or history
of alcohol abuse, in whom it is usually precipitated by bacter-
ial infection like puerperal sepsis, chronic diarrhea, and fever
or by surgery. Even infants on parenteral nutrition develop
this condition. Dilated superﬁcial veins in abdomen with
upward blood ﬂow are observed (Figure 4). US/CD examina-
tion is diagnostic (75). It shows hepatomegaly and ascites
often with evidence of bacterial peritonitis, free-ﬂoating
particles that settle on standing, acute peritonitis and thick
peritoneum with adhesions, loculations, or evidence of peri-
hepatitis indicating chronic peritonitis (Figure 5). Segmental
stenosis of medium-sized intra-HVs and prominent main
HVs with obstruction to blood ﬂow at the HV outlets will
Figure 3.Hepatic vena cava syndrome: Ultrasonography of a
young patient with ascites showing localized stenosis of upper
segment of IVC with distal dilated segment of the IVC ﬁlled
with recent and old organized thrombi. ASC, ascites; IVC,
inferior vena cava; OT, organized thrombus; RA, right
atrium; T, thrombus. (Copyright: Santosh Man Shrestha).
Figure 4. Dilated superﬁcial veins in lower abdomen with
upward ﬂow in a patient with chronic HVCS who developed
ascites from severe acute exacerbation. Patient had neutro-
phil leukocytosis and very high level of CRP and ascitic
ﬂuid had high protein content, high SAAG, and very high
absolute neutrophil count. Patient recovered from treatment
with diuretics and antibiotic for 8 weeks. (Copyright: Santosh
Man Shrestha).
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be demonstrated in US/CD. IVC at the site of HV outlet
shows stenosis with thick posterior wall with recent and old
organized thrombi of different ages along its posterior wall
(Figure 6). Gallbladder wall is thick and edematous. Neutro-
phil leukocytosis or left shift and high level of CRP are com-
mon at the onset. Bedside inoculations of blood and ascitic
ﬂuid in aerobic blood culture bottle during the initial visit
are likely to yield positive culture. Hypersplenism is common
in patients with HVCS. Such patients presenting with acute
ascites may have normal or slightly elevated WBC count
but low platelet count. Levels of serum bilirubin, alanine,
and aspartate aminotransferase will be elevated. Cavogram
and liver biopsy are not necessary for diagnosis. HVCS
patient without ascites usually have normal levels of bilirubin,
alanine, and aspartate aminotransferase, but US/CD exami-
nation shows IVC with localized stenosis with thick echoic
posterior wall in at the level of HV outlet and old organized
thrombi along the posterior wall of the distal dilated segment.
Acute onset of high-protein-content ascites in young
female patients, especially Caucasians with risk factor for
thrombosis, is likely to be due to BCS. BCS patients with
myeloproliferative disorders have, on average, higher platelet
counts and a larger spleen. US/CD imaging of liver will show
features of HV obstruction similar to HVCS, but IVC will be
normal or narrowed by caudate lobe enlargement without
organized thrombus along its posterior wall, bacterial perito-
nitis or edematous gallbladder wall.
US and CD imaging should be the ﬁrst diagnostic tests per-
formed in patients suspected of HVOO. These tests are not
only sensitive and speciﬁc but also relatively low cost, widely
available, and non-invasive with complete lack of harm and
minimal technical difﬁculty. Limitations lie in the patients’
body habitus that may preclude complete sonographic eva-
luation and the lack of experience on the part of the examiner
in diagnosis of HVCS. US and CD help in the differential
diagnosis of patients presenting with ascites in developing
countries when combined with simple laboratory tests such
as WBC and platelet counts; CRP, bilirubin, and alanine/
aspartate aminotransferase estimations; ascitic ﬂuid examina-
tion for protein, albumin; and bedside culture inoculation in
aerobic culture bottle.
In the West, where alcoholic cirrhosis is common, ascites
develops late and is considered an indication of hepatic
decompensation and liver transplantation. According to
Epstein, there is no connection between hepatic decompensa-
tion and disturbance in renal sodium handling leading to
ascites (76). In developing countries, HVCS is a common
comorbid condition in patients with LC and HCC related
to chronic hepatitis B and C or alcohol (77). Development
of ascites in LC patient may be due to severe AE of associated
HVCS that responds to medical treatment. Therefore,
LC patient in developing countries who develops ascites
and jaundice should not straightaway be referred for liver
transplantation.
Figure 5. Ultrasonography and color Doppler of a patient with HVCS showing ascites with evidence of chronic peritonitis—
Multiple intraperitoneal adhesions. Note the thrombosed, medium-sized branches of portal veins. ASC, ascites. (Copyright:
Santosh Man Shrestha).
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Conclusion
HVOO is classiﬁed into primary and secondary. Three primary
diseases of HVOO are recognized: SOS, BCS, and HVCS.
Almost all cases of HVOO seen in clinical practice belong to
these three primary diseases. Among these, SOS and BCS are
rare and seen exclusively in a particular subset of population:
SOS in patients on myeloablative therapy and BCS in young
women with hypercoagulable state. HVCS is endemic in devel-
oping countries where it is a common cause of ascites and LC.
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